Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT04724031
What this trial is testing

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hellenic Cooperative Oncology Group 150
Large-scale testing (Phase 3)Study completedNCT02106546
What this trial is testing

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Who this might be right for
Squamous Non-Small Cell Lung Cancer
AbbVie 970
Testing effectiveness (Phase 2)Active Not RecruitingNCT03368729
What this trial is testing

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Positive Breast Carcinoma
University of Alabama at Birmingham 46
Testing effectiveness (Phase 2)Study completedNCT02401347
What this trial is testing

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Who this might be right for
Advanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer
Melinda Telli 21
Early research (Phase 1)Study completedNCT00516373
What this trial is testing

Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Who this might be right for
Ovarian NeoplasmsBRCA1 ProteinBRCA2 Protein
AstraZeneca 98
Testing effectiveness (Phase 2)Looking for participantsNCT05071937
What this trial is testing

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Alexander B Olawaiye, MD 33
Large-scale testing (Phase 3)Study completedNCT03534453
What this trial is testing

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Who this might be right for
Relapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyPlatinum Sensitive
AstraZeneca 229
Testing effectiveness (Phase 2)Looking for participantsNCT05983237
What this trial is testing

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Who this might be right for
Melanoma
Jun Guo 50
Testing effectiveness (Phase 2)Study completedNCT03958045
What this trial is testing

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Who this might be right for
Small Cell Lung Cancer
Zhonglin Hao 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT04910022
What this trial is testing

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Who this might be right for
GlioblastomaDiffuse Glioma
Nerviano Medical Sciences 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07370818
What this trial is testing

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Onconic Therapeutics Inc. 81
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06544460
What this trial is testing

Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients

Who this might be right for
Ovarian Cancer
Fudan University 94
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Early research (Phase 1)Looking for participantsNCT06976892
What this trial is testing

Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

Who this might be right for
High Grade Serous Ovarian Cancer
Institute of Cancer Research, United Kingdom 33
Testing effectiveness (Phase 2)Study completedNCT02657889
What this trial is testing

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Who this might be right for
NeoplasmsTriple Negative Breast CancerOvarian Cancer+6 more
Tesaro, Inc. 122
Testing effectiveness (Phase 2)Study completedNCT03025035
What this trial is testing

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Who this might be right for
Breast Cancer
Yuan Yuan 14
Early research (Phase 1)Ended earlyNCT04267939
What this trial is testing

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Who this might be right for
Advanced Solid Tumors (Excluding Prostate Cancer)Ovarian Cancer
Bayer 14
Large-scale testing (Phase 3)Study completedNCT02163694
What this trial is testing

Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 513
Not applicableStudy completedNCT04573933
What this trial is testing

Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.

Who this might be right for
Ovarian Neoplasm
University Hospital, Brest 54
Not applicableUnknownNCT05116579
What this trial is testing

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University 30
Next Page